Lexicon Pharmaceuticals
From Wikipedia, the free encyclopedia
 |
This article needs additional citations for verification. Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (September 2007) |
| Lexicon Pharmaceuticals | |
|---|---|
 |
|
| Type | Public (NASDAQ: LXRX) |
| Founded | The Woodlands, TX, 1995 |
| Headquarters | The Woodlands, USA |
| Key people | Arthur T. Sands, CEO Alan J. Main, VP |
| Industry | Health Care |
| Employees | 600 (2007) |
| Website | www.lexpharma.com |
Lexicon Pharmaceuticals (Nasdaq LXRX) is a medium sized biopharmaceuticals company founded in The Woodlands, Texas that started operation in 1995 during the biotech bubble under the name Lexicon Genetics. Their early business emphasized the use of their patented mouse knockout technology and extensive in vivo screening to identify potential therapeutic targets[1]. In June, 2003 Lexicon Genetics purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey[2], and in 2007, they changed their name to Lexicon Pharmaceuticals to reflect their renewed focus on drug development.
[edit] References
- ^ Zambrowicz, BP; Sands, AT (2003). Knockouts model the 100 best-selling drugs--will they model the next 100? Nature Reviews of Drug Discovery. 2 (1): 38 - 51
- ^ United States Securities and Exchange Commission
 |
This corporation or company article is a stub. You can help Wikipedia by expanding it. |
